Patients with organ or islet transplants live with the life-long possibility of rejection, whereas recipients of HCT face the reverse problem: GVHD (where the newly-transplanted immune system attacks the body). The immunosuppressive medications that keep rejection and chronic GVHD at bay are inadequate and do so by suppressing all immune responses, leaving patients at high risk of infections. These medications are also associated with detrimental side effects such as cardiovascular disease, diabetes, hypertension, renal toxicity and cancer. Patients have identified the inadequacy of current medications and their toxic side-effects as a top research priority.

Patients with organ or islet transplants live with the life-long possibility of rejection, whereas recipients of HCT face the reverse problem: GVHD (where the newly-transplanted immune system attacks the body). The immunosuppressive medications that keep rejection and chronic GVHD at bay are inadequate and do so by suppressing all immune responses, leaving patients at high risk of infections. These medications are also associated with detrimental side effects such as cardiovascular disease, diabetes, hypertension, renal toxicity and cancer. Patients have identified the inadequacy of current medications and their toxic side-effects as a top research priority.

Members Fields of Expertise

  • Basic Science

  • Cardiology

  • Immunology

  • Infectious Diseases

  • Nephrology

  • Pathology

Members Research Interests

  • Bioinformatics

  • Epidemiology

  • Gene Expression Technologies

  • Genetics & Genomics

  • Immunoregulation

  • Laboratory Medicine

  • Organ Rejection

  • Proteomics

  • Transplant Surgery

  • Virology & Immunology

Theme Leaders

Mamatha Bhat
Mamatha BhatAcademic Lead
Jonathan Choy
Jonathan ChoyAcademic Lead
Elaine Yong
Elaine YongFamily Patient Lead